Loading…
Reported covered position: Policy Advisor - Committee on the Budget, United States House of Representatives
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CENTENE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to ACA, Medicare Advantage, and Medicaid Issues related to Artificial Intelligence in healthcare P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation Healthcare premium tax credits
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: RED ROCK RESORTS, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TULANE UNIVERSITY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to funding and regulations impacting higher education institutions Medicaid policies affecting University Hospitals Facilities and Administrative reimbursement issues Monitoring around negotiated rule making Education policy matters at the Dept of Education Office of the Secretary
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
CENCORA, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Source: Senate LDA
| CENTENE CORPORATION |
| 17 |
| 2022–2026 |
| LILLY USA, LLC | 17 | 2022–2026 |
| CENCORA, INC. | 14 | 2023–2026 |
| CONSENSUS CLOUD SOLUTIONS | 14 | 2023–2026 |
| FERRING PHARMACEUTICALS, INC. | 14 | 2023–2026 |
| PERNOD RICARD USA | 14 | 2023–2026 |
| TEXAS CHILDREN'S HOSPITAL | 14 | 2023–2026 |
| UNIVERSITY OF COLORADO HEALTH | 14 | 2023–2026 |
| TENET BUSINESS SERVICES CORPORATION | 13 | 2023–2026 |
| NORTHERN COMPASS GROUP LLC OBO PETERSBURG MEDICAL CENTER | 11 | 2024–2026 |
| Cepheid | 10 | 2022–2024 |
| HARMONY BIOSCIENCES | 10 | 2024–2026 |
| NATIONAL MENTOR HOLDINGS, INC. | 10 | 2022–2024 |
| TEXTILE RENTAL SERVICES ASSOCIATION | 9 | 2021–2023 |
| CAREDX, INC. | 8 | 2022–2023 |
| Enovis Corporation | 8 | 2022–2024 |
| MONOGRAM HEALTH | 8 | 2021–2023 |
| ROMARK GLOBAL PHARMA, LLC | 8 | 2022–2023 |
| ADVANCING MENTAL HEALTH FOR MILITARY FAMILIES, LLC | 7 | 2025–2026 |
| MEDIVANT HEALTHCARE | 7 | 2021–2022 |
| PIM BRANDS | 7 | 2025–2026 |
| RELX INC. | 7 | 2022–2023 |
| ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS | 7 | 2025–2026 |
| THE JEWISH FEDERATIONS OF NORTH AMERICA | 7 | 2025–2026 |
| WALGREEN CO | 7 | 2022–2023 |
| AMFAR THE FOUNDATION FOR AIDS RESEARCH | 6 | 2022–2023 |
| ENVOY MEDICAL CORPORATION | 6 | 2023–2024 |
| NMAC (ON BEHALF OF THE HIV/STD PARTNERSHIP) | 6 | 2021–2022 |
| THE SCOTTS MIRACLE-GRO COMPANY | 6 | 2024–2025 |
| TULANE UNIVERSITY | 6 | 2025–2026 |
| WECONNECT HEALTH MANAGEMENT | 6 | 2021–2022 |
| ADITXT INC. | 5 | 2021–2022 |
| ANTHEM, INC. | 5 | 2021–2022 |
| DEACON HEALTH | 5 | 2025–2026 |
| DUCKS UNLIMITED, INC. | 5 | 2024 |
| MARIDOSE LLC | 5 | 2023–2024 |
| PARTICLE HEALTH | 5 | 2024–2025 |
| SPARK THERAPEUTICS, INC. | 5 | 2024–2025 |
| AIPHARMA GLOBAL HOLDINGS LIMITED | 4 | 2021–2022 |
| ARDENT HEALTH SERVICES | 4 | 2025–2026 |
| BRENTWOOD SCHOOL | 4 | 2023–2024 |
| JACOBS ENGINEERING GROUP INC. | 4 | 2022–2023 |
| KYVERNA THERAPEUTICS, INC. | 4 | 2026 |
| MODERNA US INC. | 4 | 2023 |
| MUSCLESOUND, INC. | 4 | 2025–2026 |
| NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.)-CHA | 4 | 2025–2026 |
| PIERRE FABRE PHARMACEUTICALS, INC. | 4 | 2025–2026 |
| Red Rock Resorts, Inc. | 4 | 2025–2026 |
| AEGLE CORPORATION | 3 | 2021 |
| ALLEGIS, REDWOOD, MAXIM PUBLIC AFFAIRS, LLC | 3 | 2024 |
| ASANA VOICES, FORMERLY REPORTED AS, ASANA VOICES, LLC | 3 | 2026 |
| CONNOLLY ENTERPRISES LLC | 3 | 2022 |
| LEARNED HAND | 3 | 2025 |
| SOLVD HEALTH | 3 | 2023 |
| AMERICAN POPS ORCHESTRA | 2 | 2025 |
| BECTON, DICKINSON AND COMPANY | 2 | 2026 |
| CINNAMON HEALTH | 2 | 2025 |
| NATIONAL RESILIENCE, INC. | 2 | 2023 |
| ROMER INSTITUTE OF STROKE AND NEUROLOGY (RISN) | 2 | 2026 |
| TOLMAR, INC. | 2 | 2026 |
| BAYLOR COLLEGE OF MEDICINE | 1 | 2025 |
| CAREQUEST INSTITUTE FOR ORAL HEALTH, INC. | 1 | 2026 |
| CLEAR | 1 | 2025 |
| COGITATIVO, INC. | 1 | 2023 |
| COMPASS CONNECTIONS | 1 | 2023 |
| COMPASS UNITED | 1 | 2023 |
| EDERA L3C | 1 | 2026 |
| JACKSON FAMILY ENTERPRISES | 1 | 2024 |
| MEDEXPERT INTERNATIONAL, INC. | 1 | 2026 |
| N-DRIP INC. | 1 | 2023 |
| PATHEMAGX | 1 | 2021 |
| TYSON FOODS, INC. | 1 | 2025 |
| UNITED STATES CANNABIS COUNCIL FRA CANNABIS TRADE FEDERATION | 1 | 2022 |
Education and background on issues affecting the gaming industry H.R.2233 - SLOT Act of 2025 Form W-2G reporting requirements P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation H.R.4304 - Fair Accounting for Income Realized from Betting Earnings Taxation Act H.R.1440 - Discriminatory Gaming Tax Repeal Act of 2025 H.R.4630/ S.2773 WAGER Act of 2025 H.R. 6985 / S.2230 Facilitating Useful Loss Limitations to Help Our Unique Service Economy (FULL HOUSE) Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CENTENE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to ACA, Medicare Advantage, and Medicaid Issues related to Artificial Intelligence in healthcare P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation Healthcare premium tax credits Pharmacy contracts for long term care (LTC)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ARDENT HEALTH SERVICES · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Medicare coverage and reimbursement issues Medicaid coverage issues Medicaid provider tax State directed payments Enhanced premium tax credit P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation
Discriminatory Gaming Tax Repeal Act of 2025
Client: RED ROCK RESORTS, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Education and background on issues affecting the gaming industry H.R.2233 - SLOT Act of 2025 Form W-2G reporting requirements P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation H.R.4304 - Fair Accounting for Income Realized from Betting Earnings Taxation Act H.R.1440 - Discriminatory Gaming Tax Repeal Act of 2025 H.R.4630/ S.2773 WAGER Act of 2025 H.R. 6985 / S.2230 Facilitating Useful Loss Limitations to Help Our Unique Service Economy (FULL HOUSE) Act
Public Safety Employer-Employee Cooperation Act
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
No Stolen Trademarks Act HR 1505 Agriculture policy
Public Safety Employer-Employee Cooperation Act
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
No Stolen Trademarks Act HR 1505 Agriculture policy
Public Safety Employer-Employee Cooperation Act
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to dietary guidelines No Stolen Trademarks Act HR 1505 Agriculture policy
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy Tribal health issues
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
SLOT Act of 2025
Client: RED ROCK RESORTS, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Education and background on issues affecting the gaming industry H.R.2233 - SLOT Act of 2025 Form W-2G reporting requirements P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation H.R.4304 - Fair Accounting for Income Realized from Betting Earnings Taxation Act H.R.1440 - Discriminatory Gaming Tax Repeal Act of 2025 H.R.4630/ S.2773 WAGER Act of 2025 H.R. 6985 / S.2230 Facilitating Useful Loss Limitations to Help Our Unique Service Economy (FULL HOUSE) Act
Recognizing Community Organizations for Veteran Engagement and Recovery Act
Client: ADVANCING MENTAL HEALTH FOR MILITARY FAMILIES, LLC · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Advocating for increased access to outpatient mental health care services provided in community settings for veterans, active duty servicemembers, and their families who are in need of treatment for mental health issues (depression, anxiety, and PTSD). Specifically, advocating for enactment of H.R. 2283, the RECOVER Act, which would permit VA to contract with outpatient community providers to deliver evidence-based mental health treatment.
Recognizing Community Organizations for Veteran Engagement and Recovery Act
Client: ADVANCING MENTAL HEALTH FOR MILITARY FAMILIES, LLC · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Advocating for increased access to outpatient mental health care services provided in community settings for veterans, active duty servicemembers, and their families who are in need of treatment for mental health issues (depression, anxiety, and PTSD). Specifically, advocating for enactment of H.R. 2283, the RECOVER Act, which would permit VA to contract with outpatient community providers to deliver evidence-based mental health treatment.
Recognizing Community Organizations for Veteran Engagement and Recovery Act
Client: ADVANCING MENTAL HEALTH FOR MILITARY FAMILIES, LLC · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Advocating for increased access to outpatient mental health care services provided in community settings for veterans, active duty servicemembers, and their families who are in need of treatment for mental health issues (depression, anxiety, and PTSD). Specifically, advocating for enactment of H.R. 2283, the RECOVER Act, which would permit VA to contract with outpatient community providers to deliver evidence-based mental health treatment.
Rural healthcare coverage and reimbursement Student loan repayment Competition issues Healthcare workforce and staffing issues Medicare and Medicaid reimbursement Medicaid provider tax State directed payments Rural Health Transformation Fund H.R.3108/ S.1535 RPM Access Act
Fair Accounting for Income Realized from Betting Earnings Taxation Act
Client: RED ROCK RESORTS, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Education and background on issues affecting the gaming industry H.R.2233 - SLOT Act of 2025 Form W-2G reporting requirements P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation H.R.4304 - Fair Accounting for Income Realized from Betting Earnings Taxation Act H.R.1440 - Discriminatory Gaming Tax Repeal Act of 2025 H.R.4630/ S.2773 WAGER Act of 2025 H.R. 6985 / S.2230 Facilitating Useful Loss Limitations to Help Our Unique Service Economy (FULL HOUSE) Act
WAGER Act of 2025
Client: RED ROCK RESORTS, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Education and background on issues affecting the gaming industry H.R.2233 - SLOT Act of 2025 Form W-2G reporting requirements P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation H.R.4304 - Fair Accounting for Income Realized from Betting Earnings Taxation Act H.R.1440 - Discriminatory Gaming Tax Repeal Act of 2025 H.R.4630/ S.2773 WAGER Act of 2025 H.R. 6985 / S.2230 Facilitating Useful Loss Limitations to Help Our Unique Service Economy (FULL HOUSE) Act
Facilitating Useful Loss Limitations to Help Our Unique Service Economy (FULL HOUSE) Act
Client: RED ROCK RESORTS, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Education and background on issues affecting the gaming industry H.R.2233 - SLOT Act of 2025 Form W-2G reporting requirements P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation H.R.4304 - Fair Accounting for Income Realized from Betting Earnings Taxation Act H.R.1440 - Discriminatory Gaming Tax Repeal Act of 2025 H.R.4630/ S.2773 WAGER Act of 2025 H.R. 6985 / S.2230 Facilitating Useful Loss Limitations to Help Our Unique Service Economy (FULL HOUSE) Act
Rural Patient Monitoring (RPM) Access Act
Client: LIFEPOINT HEALTH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Rural healthcare coverage and reimbursement Student loan repayment Competition issues Healthcare workforce and staffing issues Medicare and Medicaid reimbursement Medicaid provider tax State directed payments Rural Health Transformation Fund H.R.3108/ S.1535 RPM Access Act
Facilitating Useful Loss Limitations to Help Our Unique Service Economy (FULL HOUSE) Act
Client: RED ROCK RESORTS, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Education and background on issues affecting the gaming industry H.R.2233 - SLOT Act of 2025 Form W-2G reporting requirements P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation H.R.4304 - Fair Accounting for Income Realized from Betting Earnings Taxation Act H.R.1440 - Discriminatory Gaming Tax Repeal Act of 2025 H.R.4630/ S.2773 WAGER Act of 2025 H.R. 6985 / S.2230 Facilitating Useful Loss Limitations to Help Our Unique Service Economy (FULL HOUSE) Act
Patients Deserve Price Tags Act
Client: UNIVERSITY OF COLORADO HEALTH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to Medicare coverage and reimbursement Issues related to hospital reforms and price transparency Medicaid provider tax issue State directed payments S.2355 - Patients Deserve Price Tags Act
Education and background on issues affecting the gaming industry H.R.2233 - SLOT Act of 2025 Form W-2G reporting requirements P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation H.R.4304 - Fair Accounting for Income Realized from Betting Earnings Taxation Act H.R.1440 - Discriminatory Gaming Tax Repeal Act of 2025 H.R.4630/ S.2773 WAGER Act of 2025 H.R. 6985 / S.2230 Facilitating Useful Loss Limitations to Help Our Unique Service Economy (FULL HOUSE) Act
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act issues related to DoD Procurement
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act
Stroke Act
Client: ROMER INSTITUTE OF STROKE AND NEUROLOGY (RISN) · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Strategy to establish a CMMI pilot program related to stroke recovery and advocacy around the Stroke Act (S. 5260).
Stroke Act
Client: ROMER INSTITUTE OF STROKE AND NEUROLOGY (RISN) · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Strategy to establish a CMMI pilot program related to stroke recovery and advocacy around the Stroke Act (S. 5260).
Advancing legislation on cardiovascular health and related issues. S.5469 HEART Foundation Act
A bill to amend the Harmonized Tariff Schedule of the United States to provide a uniform 8-digit subheading number for all whiskies.
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act
A bill to amend the Harmonized Tariff Schedule of the United States to provide a uniform 8-digit subheading number for all whiskies.
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act issues related to DoD Procurement
A bill to amend the Harmonized Tariff Schedule of the United States to provide a uniform 8-digit subheading number for all whiskies.
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ARDENT HEALTH SERVICES · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Medicare coverage and reimbursement issues Medicaid coverage issues Medicaid provider tax State directed payments enhanced premium tax credit H.R.1 One Big Beautiful Bill
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: RED ROCK RESORTS, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Education and background on issues affecting the gaming industry Reconciliation provision relating to new proposed new section 899 of the Tax Code H.R.2233 - SLOT Act of 2025 Form W-2G reporting requirements H.R. 1 Implementation
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: RED ROCK RESORTS, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Education and background on issues affecting the gaming industry H.R.2233 - SLOT Act of 2025 Form W-2G reporting requirements P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CENTENE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to ACA, Medicare Advantage, and Medicaid Issues related to Artificial Intelligence in healthcare P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation Healthcare premium tax credits
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ARDENT HEALTH SERVICES · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Medicare coverage and reimbursement issues Medicaid coverage issues Medicaid provider tax State directed payments enhanced premium tax credit H.R.1 implementation
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CENTENE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to ACA, Medicare Advantage, and Medicaid General mental health policy Issues related to Artificial Intelligence in healthcare H.R.1 One Big Beautiful Bill
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: CENTENE CORPORATION · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to ACA, Medicare Advantage, and Medicaid General mental health policy Issues related to Artificial Intelligence in healthcare H.R.1 implementation Healthcare premium tax credits
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ARDENT HEALTH SERVICES · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Medicare coverage and reimbursement issues Medicaid coverage issues Medicaid provider tax State directed payments Enhanced premium tax credit P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation
Public Safety Employer-Employee Cooperation Act
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to dietary guidelines No Stolen Trademarks Act HR 1505
Public Safety Employer-Employee Cooperation Act
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to dietary guidelines No Stolen Trademarks Act HR 1505
Public Safety Employer-Employee Cooperation Act
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to dietary guidelines No Stolen Trademarks Act HR 1505
Public Safety Employer-Employee Cooperation Act
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to dietary guidelines No Stolen Trademarks Act HR 1505
Public Safety Employer-Employee Cooperation Act
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to dietary guidelines No Stolen Trademarks Act HR 1505
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
SLOT Act of 2025
Client: RED ROCK RESORTS, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Education and background on issues affecting the gaming industry Reconciliation provision relating to new proposed new section 899 of the Tax Code H.R.2233 - SLOT Act of 2025 Form W-2G reporting requirements H.R. 1 Implementation
SLOT Act of 2025
Client: RED ROCK RESORTS, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Education and background on issues affecting the gaming industry H.R.2233 - SLOT Act of 2025 Form W-2G reporting requirements P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation
Recognizing Community Organizations for Veteran Engagement and Recovery Act
Client: ADVANCING MENTAL HEALTH FOR MILITARY FAMILIES, LLC · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Advocating for increased access to outpatient mental health care services provided in community settings for veterans, active duty servicemembers, and their families who are in need of treatment for mental health issues (depression, anxiety, and PTSD). Specifically, advocating for enactment of H.R. 2283, the RECOVER Act, which would permit VA to contract with outpatient community providers to deliver evidence-based mental health treatment.
Recognizing Community Organizations for Veteran Engagement and Recovery Act
Client: ADVANCING MENTAL HEALTH FOR MILITARY FAMILIES, LLC · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Advocating for increased access to outpatient mental health care services provided in community settings for veterans, active duty servicemembers, and their families who are in need of treatment for mental health issues (depression, anxiety, and PTSD). Specifically, advocating for enactment of H.R. 2283, the RECOVER Act, which would permit VA to contract with outpatient community providers to deliver evidence-based mental health treatment.
Recognizing Community Organizations for Veteran Engagement and Recovery Act
Client: ADVANCING MENTAL HEALTH FOR MILITARY FAMILIES, LLC · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Advocating for increased access to outpatient mental health care services provided in community settings for veterans, active duty servicemembers, and their families who are in need of treatment for mental health issues (depression, anxiety, and PTSD). Specifically, advocating for enactment of H.R. 2283, the RECOVER Act, which would permit VA to contract with outpatient community providers to deliver evidence-based mental health treatment.
Recognizing Community Organizations for Veteran Engagement and Recovery Act
Client: ADVANCING MENTAL HEALTH FOR MILITARY FAMILIES, LLC · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Advocating for increased access to outpatient mental health care services provided in community settings for veterans, active duty servicemembers, and their families who are in need of treatment for mental health issues (depression, anxiety, and PTSD). Specifically, advocating for enactment of H.R. 2283, the RECOVER Act, which would permit VA to contract with outpatient community providers to deliver evidence-based mental health treatment.
Recognizing Community Organizations for Veteran Engagement and Recovery Act
Client: ADVANCING MENTAL HEALTH FOR MILITARY FAMILIES, LLC · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Advocating for increased access to outpatient mental health care services provided in community settings for veterans, active duty servicemembers, and their families who are in need of treatment for mental health issues (depression, anxiety, and PTSD). Specifically, advocating for enactment of H.R. 2283, the RECOVER Act, which would permit VA to contract with outpatient community providers to deliver evidence-based mental health treatment.
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act Issues related to DoD procurement
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act issues related to DoD Procurement
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act
A bill to amend the Harmonized Tariff Schedule of the United States to provide a uniform 8-digit subheading number for all whiskies.
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act
A bill to amend the Harmonized Tariff Schedule of the United States to provide a uniform 8-digit subheading number for all whiskies.
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act issues related to DoD Procurement
A bill to amend the Harmonized Tariff Schedule of the United States to provide a uniform 8-digit subheading number for all whiskies.
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act
A bill to amend the Harmonized Tariff Schedule of the United States to provide a uniform 8-digit subheading number for all whiskies.
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act
A bill to amend the Harmonized Tariff Schedule of the United States to provide a uniform 8-digit subheading number for all whiskies.
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act Issues related to DoD procurement
To amend the Internal Revenue Code of 1986 to clarify the definition of applicable educational institution for purposes of the excise tax based on the income of private colleges and universities.
Client: BAYLOR COLLEGE OF MEDICINE · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to excise tax under section 4968 of the Internal Revenue Code The Bipartisan Workforce Pell Act College Cost Reduction Act H.R. 10400 To amend the Internal Revenue Code of 1986 to clarify the definition of applicable educational institution for purposes of the excise tax based on the income of private colleges and universities.
SAFER Banking Act
Client: THE SCOTTS MIRACLE-GRO COMPANY · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cannabis and S.2860 The Safer Banking Act Issues related to IRC Section 280E General corporate tax issues TCJA Extension
SAFER Banking Act
Client: THE SCOTTS MIRACLE-GRO COMPANY · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cannabis and S.2860 The Safer Banking Act Issues related to IRC Section 280E General corporate tax issues TCJA Extension
No Stolen Trademarks Honored in America Act of 2023
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to the FARM bill Issues related to dietary guidelines No Stolen Trademarks Act HR 1505
No Stolen Trademarks Honored in America Act of 2023
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to the FARM bill Issues related to dietary guidelines No Stolen Trademarks Act HR 1505
Equitable Community Access to Pharmacist Services Act
Client: CENCORA, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Recognizing pharmacists as providers within Medicare; The Equitable Community Access to Pharmacist Services Act (H.R.1770/S. 2477; Medicare reimbursement.
Equitable Community Access to Pharmacist Services Act
Client: CENCORA, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Recognizing pharmacists as providers within Medicare; The Equitable Community Access to Pharmacist Services Act (H.R.1770/S. 2477; Medicare reimbursement.
Equitable Community Access to Pharmacist Services Act
Client: CENCORA, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Recognizing pharmacists as providers within Medicare; The Equitable Community Access to Pharmacist Services Act (H.R.1770/S. 2477; Medicare reimbursement.
Equitable Community Access to Pharmacist Services Act
Client: CENCORA, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Recognizing pharmacists as providers within Medicare; The Equitable Community Access to Pharmacist Services Act (H.R.1770/S. 2477; Medicare reimbursement.
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to the development of gene therapies for rare diseases S. 4204/ H.R. 2666 MVP ACT
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to the development of gene therapies for rare diseases S. 4204/ H.R. 2666 MVP ACT
Medicaid VBPs for Patients Act
Client: SPARK THERAPEUTICS, INC. · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to the development of gene therapies for rare diseases S. 4204/ H.R. 2666 MVP ACT
NIH Clinical Trial Diversity Act of 2023
Client: UNIVERSITY OF COLORADO HEALTH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to Medicare coverage and reimbursement and Medicaid coverage and reimbursement H.R. 3503 NIH Clinical Trial Diversity Act of 2023
NIH Clinical Trial Diversity Act of 2023
Client: UNIVERSITY OF COLORADO HEALTH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to Medicare coverage and reimbursement and Medicaid coverage and reimbursement H.R. 3503 NIH Clinical Trial Diversity Act of 2023
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: CEPHEID · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to diagnostic testing and reimbursement related to COVID testing Issues related to the Strategic National Stockpile, supply chain, and future pandemic preparedness PREVENT Pandemics Act FY 2024 Appropriations PASTEUR ACT/ Issues related to antimicrobial resistance Issues related to adoption of PLA codes Pandemic and All-Hazards Preparedness Act Reauthorization H.R. 3795 To amend the Public Health Service Act Alzheimer's testing Tuberculosis testing
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: CEPHEID · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to diagnostic testing and reimbursement. Issues related to the Strategic National Stockpile, supply chain, and future pandemic preparedness PREVENT Pandemics Act FY 2024 Appropriations PASTEUR ACT/ Issues related to antimicrobial resistance Issues related to adoption of PLA codes Pandemic and All-Hazards Preparedness Act Reauthorization H.R. 3795 To amend the Public Health Service Act Alzheimer's testing issues related to hepatitis-C including HEP-C testing
To amend the Public Health Service Act to require the development of a diagnostic testing preparedness plan to be used during public health emergencies, and for other purposes.
Client: CEPHEID · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to diagnostic testing and reimbursement. Issues related to the Strategic National Stockpile, supply chain, and future pandemic preparedness PREVENT Pandemics Act FY 2024 Appropriations PASTEUR ACT/ Issues related to antimicrobial resistance Issues related to adoption of PLA codes Pandemic and All-Hazards Preparedness Act Reauthorization H.R. 3795 To amend the Public Health Service Act issues related to hepatitis-C including HEP-C testing
Housing our Military Veterans Effectively Act of 2023
Client: BRENTWOOD SCHOOL · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to the Department of Veterans Affairs Report #18-00474-300 H.R.3848 HOME Act of 2023
Housing our Military Veterans Effectively Act of 2023
Client: BRENTWOOD SCHOOL · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to the Department of Veterans Affairs Report #18-00474-300 H.R.3848 HOME Act of 2023
Duty Drawback Clarification Act
Client: PERNOD RICARD USA · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Alcohol excise taxes HR 4073 and S. 1781 To clarify the treatment of drawback in distilled spirits, and for other purposes Issues related to dietary guidelines Corporate minimum tax
Treat and Reduce Obesity Act of 2023
Client: LILLY USA, LLC · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation H.R. 4818 Treat and Reduce Obesity Act
Treat and Reduce Obesity Act of 2023
Client: LILLY USA, LLC · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation H.R. 4818 Treat and Reduce Obesity Act
Treat and Reduce Obesity Act of 2023
Client: LILLY USA, LLC · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation H.R. 4818 Treat and Reduce Obesity Act
Treat and Reduce Obesity Act of 2023
Client: LILLY USA, LLC · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation H.R. 4818 Treat and Reduce Obesity Act
Expanding Remote Monitoring Access Act
Client: TAPESTRYHEALTH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to telehealth Telehealth Extension and Evaluation Act Physician coverage and reimbursement issues Remote monitoring H.R. 5394, the Expanding Remote Monitoring Access Act H.R. 6801: RPM Cost Sharing Elimination Study Act of 2023
Expanding Remote Monitoring Access Act
Client: TAPESTRYHEALTH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to telehealth Telehealth Extension and Evaluation Act Physician coverage and reimbursement issues Remote monitoring H.R. 5394, the Expanding Remote Monitoring Access Act H.R. 6801: RPM Cost Sharing Elimination Study Act of 2023
Expanding Remote Monitoring Access Act
Client: TAPESTRYHEALTH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to telehealth Telehealth Extension and Evaluation Act Physician coverage and reimbursement issues Remote monitoring H.R. 5394, the Expanding Remote Monitoring Access Act H.R. 6801: RPM Cost Sharing Elimination Study Act of 2023
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues S. 476/H.R.5547 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues S. 476/H.R.5547 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues S. 476/H.R.5547 The Maintaining Investments in New Innovations (MINI) Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues S. 476/H.R.5547 The Maintaining Investments in New Innovations (MINI) Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues S. 476/H.R.5547 The Maintaining Investments in New Innovations (MINI) Act
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to cell and gene therapy Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues S. 476/H.R.5547 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues
RPM Cost Sharing Elimination Study Act of 2023
Client: TAPESTRYHEALTH · Firm: BROWNSTEIN HYATT FARBER SCHRECK, LLP
Issues related to telehealth Telehealth Extension and Evaluation Act Physician coverage and reimbursement issues Remote monitoring H.R. 5394, the Expanding Remote Monitoring Access Act H.R. 6801: RPM Cost Sharing Elimination Study Act of 2023
Drug Shortages; supply chain resiliency; PAHPA Reauthorization; Drug Supply Chain Security Act (DSCSA) Implementation, SUPPORT Act Reauthorization, Appropriations bills (FDA, Labor, HHS). Issues related to vertical integration
Recognizing pharmacists as providers within Medicare; The Equitable Introduction of Community Access to Pharmacist Services Act Medicare reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PERNOD RICARD USA via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
No Stolen Trademarks Act HR 1505 Agriculture policy
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
BECTON, DICKINSON AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to medical device reimbursement.
Issues related medical technology regulation.
Filing targets: State, Dept of (DOS)
TOLMAR, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Advocacy around issues affecting the pharmaceutical industry, such as the Medicare Drug Price Negotiation Program under the Inflation Reduction Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy Tribal health issues
Filing targets: Indian Health Service, SENATE
ABBVIE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to patient access, pharmaceutical manufacturing, Patent reform, and drug pricing both domestic and international Issues realted to medicare drug pricing and reimbursement Direct to Consumer Advertising
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MEDEXPERT INTERNATIONAL, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to funding for VA technology programs and medical centers via an AI based platform to assist veterans with medical decisions
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
LIFEPOINT HEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Rural healthcare coverage and reimbursement Student loan repayment Competition issues Healthcare workforce and staffing issues Medicare and Medicaid reimbursement Medicaid provider tax State directed payments Rural Health Transformation Fund H.R.3108/ S.1535 RPM Access Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KYVERNA THERAPEUTICS, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Outreach regarding cell therapies for autoimmune diseases.
Filing targets: Health & Human Services, Dept of (HHS)
NORTHERN COMPASS GROUP LLC OBO PETERSBURG MEDICAL CENTER via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Funding for new Petersburg Medical Center facility
CENTENE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to ACA, Medicare Advantage, and Medicaid Issues related to Artificial Intelligence in healthcare issues related to healthcare affordability Regulatory policy related to LTC pharmaceutical services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to microbiome, oncology, & fertility Issues related to formulary tier status Drug pricing policy Healthcare policy in the NDAA IVF Tax credit FDA Review programs
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
PIM BRANDS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Healthcare related matters affecting the food industry. Tariffs and USMCA issues affecting the food industry issues impacting international food manufacturing
Filing targets: SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to the pharmaceutical industry Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHSPSC, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to healthcare policy Medicare area wage index Issues related to Medicare reimbursement Issues related to healthcare facility locations Medicaid provider tax State directed payments Rural healthcare workforce
Filing targets: SENATE, State, Dept of (DOS)
ROMER INSTITUTE OF STROKE AND NEUROLOGY (RISN) via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Strategy to establish a CMMI pilot program related to stroke recovery and advocacy around the Stroke Act (S. 5260).
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SOUTHEAST ALASKA REGIONAL HEALTH CONSORTIUM via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Community project funding for new medical facility design and construction
ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to pharmaceutical manufacturing Tax and trade policy affecting the pharmaceutical industry Drug pricing issues
Companys expansion of its domestic footprint.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAPESTRYHEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to telehealth Telehealth Extension and Evaluation Act Physician coverage and reimbursement issues Remote monitoring Expanding Remote Monitoring Access Act RPM Cost Sharing Elimination Study Act Physician Fee Schedule Remote patient monitoring
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
TENET BUSINESS SERVICES CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Medicare coverage and reimbursement issues Medicaid coverage issues Medicaid provider tax issue State directed payments Issues related to ASC's Graduate medical education issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ASANA VOICES via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Advancing legislation on cardiovascular health and related issues. S.5469 HEART Foundation Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TEXAS CHILDREN'S HOSPITAL via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Pediatric health care issues Medicaid coverage and reimbursement Maternal health Pediatric cancer research funding PACT ACT and CHGME Funding Global pediatric healthcare issues State directed payments
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
UNIVERSITY OF COLORADO HEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to Medicare coverage and reimbursement Issues related to hospital reforms and price transparency Medicaid provider tax issue State directed payments S.2355 - Patients Deserve Price Tags Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HARMONY BIOSCIENCES via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Issues related to the development and approval of therapies for rare diseases Pharmaceutical tariffs
Filing targets: HOUSE OF REPRESENTATIVES
ADVANCING MENTAL HEALTH FOR MILITARY FAMILIES, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Advocating for increased access to outpatient mental health care services provided in community settings for veterans, active duty servicemembers, and their families who are in need of treatment for mental health issues (depression, anxiety, and PTSD). Specifically, advocating for enactment of H.R. 2283, the RECOVER Act, which would permit VA to contract with outpatient community providers to deliver evidence-based mental health treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CAREQUEST INSTITUTE FOR ORAL HEALTH, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Oral health issues and screenings for oral cancer. Access to oral healthcare and issues related to Medicare Dental. Issues related to Medicare and Medicaid dental Fluoride Human Health Toxicity Assessment Expanded eligibility for dental care for veterans and veterans in rural areas
Filing targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, SENATE
THE JEWISH FEDERATIONS OF NORTH AMERICA via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · Q3
Anti-Semitism in healthcare Medicare and Medicaid funding, food assistance funding Proposed rulemaking impacting the Jewish community
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), White House Office
ROMER INSTITUTE OF STROKE AND NEUROLOGY (RISN) via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · RR
Strategy to establish a CMMI pilot program related to stroke recovery and advocacy around the Stroke Act (S. 5260).
BECTON, DICKINSON AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · RR
Issues related to medical technology regulation. Issues related to medical device reimbursement. Medical device supply chain and international trade issues.
Issues related to medical technology regulation. Issues related to medical device reimbursement. Medical device supply chain and international trade issues.
Issues related to medical technology regulation. Issues related to medical device reimbursement. Medical device supply chain and international trade issues.
TOLMAR, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · third_quarter · RR
Advocacy around issues affecting the pharmaceutical industry, such as the Medicare Drug Price Negotiation Program under the Inflation Reduction Act.
ASANA VOICES via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Advancing legislation on cardiovascular health and related issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NOVARTIS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Filing targets: HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR)
ABBVIE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Issues related to patient access, pharmaceutical manufacturing, Patent reform, and drug pricing both domestic and international Issues realted to medicare drug pricing and reimbursement DTC Advertising
Filing targets: HOUSE OF REPRESENTATIVES
HARMONY BIOSCIENCES via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Issues related to the development and approval of therapies for rare diseases Pharmaceutical tariffs
FERRING PHARMACEUTICALS INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Issues related to microbiome, oncology, & fertility Issues related to formulary tier status Drug pricing policy Healthcare policy in the NDAA IVF Tax credit FDA Review programs
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Issues related to the pharmaceutical industry Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
KYVERNA THERAPEUTICS, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Outreach regarding cell therapies for autoimmune diseases.
Filing targets: Food & Drug Administration (FDA), Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), White House Office
LIFEPOINT HEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Rural healthcare coverage and reimbursement Student loan repayment Competition issues Healthcare workforce and staffing issues Medicare and Medicaid reimbursement Medicaid provider tax State directed payments Rural Health Transformation Fund
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.)-CHA via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
General issues of importance to children's hospitals Adovcacy for philanthropic opportunities for children's hospitals Children's healthcare coverage and reimbursement issues Issues related to CHGME Issues related to HHS Funding Medicaid provider tax State directed payments
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NORTHERN COMPASS GROUP LLC OBO PETERSBURG MEDICAL CENTER via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Funding for new Petersburg Medical Center facility
PIM BRANDS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Healthcare related matters affecting the food industry. Tariffs and USMCA issues affecting the food industry
Filing targets: Commerce, Dept of (DOC), U.S. Trade Representative (USTR)
CHSPSC, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Issues related to healthcare policy Medicare area wage index Issues related to Medicare reimbursement Issues related to healthcare facility locations Medicaid provider tax State directed payments Rural healthcare workforce
Filing targets: HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
SOUTHEAST ALASKA REGIONAL HEALTH CONSORTIUM via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Community project funding for new medical facility design and construction
ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Companys expansion of its domestic footprint.
Issues related to pharmaceutical manufacturing Tax and trade policy affecting the pharmaceutical industry
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
TULANE UNIVERSITY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Issues related to funding and regulations impacting higher education institutions Medicaid policies affecting University Hospitals Facilities and Administrative reimbursement issues Monitoring around negotiated rule making Education policy matters at the Dept of Education Office of the Secretary
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
THE JEWISH FEDERATIONS OF NORTH AMERICA via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Anti-Semitism in healthcare Medicare and Medicaid funding, food assistance funding
Filing targets: HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), White House Office
PERNOD RICARD USA via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act
No Stolen Trademarks Act HR 1505 Agriculture policy
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), White House Office
CENTENE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Issues related to ACA, Medicare Advantage, and Medicaid Issues related to Artificial Intelligence in healthcare P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation Healthcare premium tax credits Pharmacy contracts for long term care (LTC)
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CENCORA, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Recognizing pharmacists as providers within Medicare; The Equitable Introduction of Community Access to Pharmacist Services Act Medicare reimbursement.
Drug Shortages; supply chain resiliency; PAHPA Reauthorization; Drug Supply Chain Security Act (DSCSA) Implementation, SUPPORT Act Reauthorization, Appropriations bills (FDA, Labor, HHS).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVANCING MENTAL HEALTH FOR MILITARY FAMILIES, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Advocating for increased access to outpatient mental health care services provided in community settings for veterans, active duty servicemembers, and their families who are in need of treatment for mental health issues (depression, anxiety, and PTSD). Specifically, advocating for enactment of H.R. 2283, the RECOVER Act, which would permit VA to contract with outpatient community providers to deliver evidence-based mental health treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TAPESTRYHEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Issues related to telehealth Telehealth Extension and Evaluation Act Physician coverage and reimbursement issues Remote monitoring Expanding Remote Monitoring Access Act RPM Cost Sharing Elimination Study Act Physician Fee Schedule
Filing targets: Centers For Medicare and Medicaid Services (CMS)
TENET BUSINESS SERVICES CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Medicare coverage and reimbursement issues Medicaid coverage issues Medicaid provider tax issue State directed payments Issues related to ASC's
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
TEXAS CHILDREN'S HOSPITAL via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Pediatric health care issues Medicaid coverage and reimbursement Maternal health Pediatric cancer research funding PACT ACT and CHGME Funding Global pediatric healthcare issues
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
UNIVERSITY OF COLORADO HEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · Q2
Issues related to Medicare coverage and reimbursement Issues related to hospital reforms and price transparency Medicaid provider tax issue State directed payments
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASANA VOICES via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · second_quarter · RR
Advancing legislation on cardiovascular health and related issues.
NOVARTIS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Filing targets: U.S. Trade Representative (USTR)
TULANE UNIVERSITY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to funding and regulations impacting higher education institutions Medicaid policies affecting University Hospitals Facilities and Administrative reimbursement issues Monitoring around negotiated rule making Education policy matters at the Dept of Education Office of the Secretary
Filing targets: Education, Dept of, HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE
CENTENE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to ACA, Medicare Advantage, and Medicaid Issues related to Artificial Intelligence in healthcare P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation Healthcare premium tax credits
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
KYVERNA THERAPEUTICS, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Outreach regarding cell therapies for autoimmune diseases.
LIFEPOINT HEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Rural healthcare coverage and reimbursement Student loan repayment Competition issues Healthcare workforce and staffing issues Medicare and Medicaid reimbursement Issues related to emergency response for healthcare facilities Medicaid provider tax State directed payments Rural Health Transformation Fund
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain
Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act
Filing targets: Commerce, Dept of (DOC), SENATE
FERRING PHARMACEUTICALS INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to microbiome, oncology, & fertility Issues related to formulary tier status Drug pricing policy Healthcare policy in the NDAA IVF Tax credit
Filing targets: Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
MUSCLESOUND, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to increased access to healthcare technology and malnutrition reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.)-CHA via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
General issues of importance to children's hospitals Children's healthcare coverage and reimbursement issues Issues related to CHGME Issues related to HHS Funding Medicaid provider tax State directed payments
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
SOUTHEAST ALASKA REGIONAL HEALTH CONSORTIUM via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Community project funding for new medical facility design and construction
CHSPSC, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to healthcare policy Medicare area wage index Issues related to Medicare reimbursement Issues related to healthcare facility locations Medicaid provider tax State directed payments Rural healthcare workforce
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TENET BUSINESS SERVICES CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Medicare coverage and reimbursement issues Medicaid coverage issues Medicaid provider tax issue State directed payments Issues related to ASC's
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ADVANCING MENTAL HEALTH FOR MILITARY FAMILIES, LLC via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Advocating for increased access to outpatient mental health care services provided in community settings for veterans, active duty servicemembers, and their families who are in need of treatment for mental health issues (depression, anxiety, and PTSD). Specifically, advocating for enactment of H.R. 2283, the RECOVER Act, which would permit VA to contract with outpatient community providers to deliver evidence-based mental health treatment.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
DEACON HEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to artificial intelligence, privacy, and technology affecting the healthcare communities and care giving facilities. CMMI Models
CONSENSUS CLOUD SOLUTIONS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to Healthcare, interoperability, digital cloud fax technology, and artificial intelligence
NORTHERN COMPASS GROUP LLC OBO PETERSBURG MEDICAL CENTER via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Funding for new Petersburg Medical Center facility
PERNOD RICARD USA via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to dietary guidelines No Stolen Trademarks Act HR 1505 Agriculture policy
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act issues related to DoD Procurement
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS)
HARMONY BIOSCIENCES via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to the development and approval of therapies for rare diseases Pharmaceutical tariffs
Filing targets: HOUSE OF REPRESENTATIVES
CENCORA, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Recognizing pharmacists as providers within Medicare; The Equitable Introduction of Community Access to Pharmacist Services Act Medicare reimbursement.
IRA implementation. Drug Shortages; supply chain resiliency; PAHPA Reauthorization; Drug Supply Chain Security Act (DSCSA) Implementation, SUPPORT Act Reauthorization, Appropriations bills (FDA, Labor, HHS).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ABBVIE via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to patient access, pharmaceutical manufacturing, Patent reform, and drug pricing both domestic and international Issues realted to medicare drug pricing and reimbursement DTC Advertising
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
EDERA L3C via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · RR
Healthcare IT issues and AI
PIERRE FABRE PHARMACEUTICALS INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to drug development, rare disease innovations, and issues impacting the pharmaceutical industry.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS)
PIM BRANDS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Healthcare related matters affecting the food industry. Issues related to sugar reform Tariffs affecting the food industry
Filing targets: SENATE
RED ROCK RESORTS, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Education and background on issues affecting the gaming industry H.R.2233 - SLOT Act of 2025 Form W-2G reporting requirements P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation H.R.4304 - Fair Accounting for Income Realized from Betting Earnings Taxation Act H.R.1440 - Discriminatory Gaming Tax Repeal Act of 2025 H.R.4630/ S.2773 WAGER Act of 2025 H.R. 6985 / S.2230 Facilitating Useful Loss Limitations to Help Our Unique Service Economy (FULL HOUSE) Act
Filing targets: HOUSE OF REPRESENTATIVES, Interior, Dept of (DOI), Internal Revenue Service (IRS), Labor, Dept of (DOL), Natl Credit Union Administration (NCUA), SENATE, Treasury, Dept of
ARDENT HEALTH SERVICES via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Medicare coverage and reimbursement issues Medicaid coverage issues Medicaid provider tax State directed payments Enhanced premium tax credit P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ST SHARED SERVICES LLC DBA KEENOVA THERAPEUTICS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Companys expansion of its domestic footprint.
issues related to pharmaceutical manufacturing Tax and trade policy affecting the pharmaceutical industry
Filing targets: Bureau of Industry and Security (BIS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TAPESTRYHEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to telehealth Telehealth Extension and Evaluation Act Physician coverage and reimbursement issues Remote monitoring Expanding Remote Monitoring Access Act RPM Cost Sharing Elimination Study Act
TEXAS CHILDREN'S HOSPITAL via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Pediatric health care issues Medicaid coverage and reimbursement Maternal health Pediatric cancer research funding PACT ACT and CHGME Funding Global pediatric healthcare issues
Filing targets: HOUSE OF REPRESENTATIVES, State, Dept of (DOS)
THE JEWISH FEDERATIONS OF NORTH AMERICA via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Anti-Semitism in healthcare Medicare and Medicaid funding, food assistance funding
Filing targets: HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Management & Budget (OMB), SENATE, White House Office
UNIVERSITY OF COLORADO HEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · Q1
Issues related to Medicare coverage and reimbursement Issues related to Medicaid coverage and reimbursement Issues related to hospital reforms and price transparency Medicaid provider tax issue State directed payments
KYVERNA THERAPEUTICS, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2026 · first_quarter · RR
Outreach regarding cell therapies for autoimmune diseases.
NOVARTIS via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Filing targets: HOUSE OF REPRESENTATIVES
TULANE UNIVERSITY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Issues related to funding and regulations impacting higher education institutions Medicaid policies Facilities and Administrative reimbursement issues Monitoring around negotiated rule making
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FERRING PHARMACEUTICALS INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Issues related to microbiome, oncology, & fertility Issues related to formulary tier status Drug pricing policy Healthcare policy in the NDAA Pharmaceutical tariffs
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR)
LIFEPOINT HEALTH via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Rural healthcare coverage and reimbursement Student loan repayment Competition issues Healthcare workforce and staffing issues Medicare and Medicaid reimbursement Issues related to emergency response for healthcare facilities Medicaid provider tax State directed payments
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
PERNOD RICARD USA via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Issues related to dietary guidelines No Stolen Trademarks Act HR 1505
S. 952 To clarify the treatment of drawback in distilled spirits, and for other purposes S. 488 DEMOCRACIA Act issues related to DoD Procurement
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
TENET BUSINESS SERVICES CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Medicare coverage and reimbursement issues Medicaid coverage issues Enhanced advanced premium tax credit (EAPTC) Medicaid provider tax issue State directed payments issues related to ASC's
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
THE JEWISH FEDERATIONS OF NORTH AMERICA via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Anti-Semitism in healthcare Medicare and Medicaid funding, food assistance funding
Filing targets: Executive Office of the President (EOP), Federal Emergency Management Agency (FEMA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE
CENTENE CORPORATION via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Issues related to ACA, Medicare Advantage, and Medicaid Issues related to Artificial Intelligence in healthcare P.L. 119-21 (H.R. 1): One Big Beautiful Bill implementation Healthcare premium tax credits
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation Treat and Reduce Obesity Act Pharmaceutical tariffs Safe Drugs Act
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MUSCLESOUND, INC. via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Issues related to increased access to healthcare technology and malnutrition reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
NATIONAL ASSOCIATION OF CHILDREN'S HOSPITALS (N.A.C.H.)-CHA via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
General issues of importance to children's hospitals Children's healthcare coverage and reimbursement issues Issues related to CHGME Issues related to HHS Funding Medicaid provider tax State directed payments
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
HARMONY BIOSCIENCES via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Issues related to the development and approval of therapies for rare diseases Pharmaceutical tarrifs
NORTHERN COMPASS GROUP LLC OBO PETERSBURG MEDICAL CENTER via BROWNSTEIN HYATT FARBER SCHRECK, LLP
2025 · fourth_quarter · Q4
Funding for new Petersburg Medical Center facility